TherapeuticsMD, Inc. TXMD
- Market cap
- $24.7M
- P/E
- 0.0×
Follow TXMD
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 219.50 | 175.00 | 175.50 | 91.00 | 42.50 | 17.50 | 1.99 | 1.95 | 0.70 | 0.72 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 508.50 | 415.00 | 383.00 | 304.50 | 146.50 | 137.50 | 30.50 | 6.49 | 2.75 | 2.44 |
High Price
|
|||
| 159 | 173 | 241 | 348 | 400 | 416 | 1 | 1 | 1 | 1 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 70 | 1 | 2 | 3 |
Revenue/Emp
|
|||
| 19 | 17 | 16 | 50 | 65 | 3 | 70 | 1 | 2 | 3 |
Revenue
|
|||
| 78.38% | 84.28% | 83.00% | 87.24% | 75.37% | 45.51% | 98.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| (90) | (77) | (133) | (176) | (184) | (79) | 1 | (8) | (2) | (1) |
EBT
|
|||
| (464.32%) | (458.50%) | (823.73%) | (354.79%) | (282.90%) | (3,082.20%) | 1.54% | (594.62%) | (133.05%) | (21.61%) |
EBT Margin
|
|||
| (90) | (77) | (133) | (176) | (184) | (172) | 112 | (10) | (2) | (1) |
Net Income
|
|||
| 0 | 0 | 1 | 1 | 4 | 1 | 1 | 1 | 1 | 1 |
Depreciation
|
|||
| 4.94 | 4.08 | 3.58 | 10.08 | 11.77 | 0.32 | 7.75 | 0.12 | 0.15 | 0.26 |
Revenue/Sh
|
|||
| (23.00) | (18.50) | (29.50) | (36.00) | (36.00) | (21.50) | 12.41 | (0.98) | (0.19) | (0.05) |
Earnings/Sh
|
|||
| (17.63) | (18.53) | (23.73) | (33.63) | (28.93) | (6.93) | 1.04 | (2.21) | 0.10 | 0.21 |
Cash Flow/Sh
|
|||
| (0.32) | (0.20) | (4.74) | (4.85) | (0.29) | (0.28) | (0.04) | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (17.95) | (18.73) | (28.47) | (38.48) | (29.22) | (7.21) | 1.00 | (2.21) | 0.10 | 0.21 |
Free CF/Sh
|
|||
| 32.51 | 31.60 | 21.67 | 1.87 | (22.49) | (11.76) | 3.89 | 2.81 | 2.37 | 2.32 |
Book Value/Sh
|
|||
| 4 | 4 | 5 | 5 | 6 | 8 | 9 | 10 | 12 | 12 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 60.48 | 76.81 | 53.25 | 12.01 | 5.14 | 55.69 | 0.81 | 18.68 | 5.63 | 6.24 |
PS Ratio
|
|||
| 9.18 | 9.92 | 8.79 | 64.79 | 0.00 | 0.00 | 1.61 | 0.83 | 0.36 | 0.70 |
PB Ratio
|
|||
| 53.68 | 69.23 | 47.77 | 12.72 | 7.60 | 106.76 | 1.55 | 21.66 | 7.42 | 6.48 |
EV/Sales
|
|||
| (14.76) | (15.09) | (6.00) | (3.33) | (3.06) | (4.79) | 12.05 | (1.20) | 16.45 | 9.42 |
EV/FCF
|
|||
| (69) | (76) | (107) | (166) | (159) | (55) | 9 | (23) | 1 | 2 |
Op' Cash Flow
|
|||
| (1) | (1) | (21) | (24) | (2) | (2) | 0 | — | — | — |
Capex
|
|||
| (70) | (77) | (128) | (190) | (161) | (57) | 9 | (23) | 1 | 2 |
FCF
|
|||
| 124 | 126 | 146 | 155 | 69 | (133) | 9 | 5 | 7 | 10 |
Working Cap'
|
|||
| — | — | 73 | 196 | 240 | 196 | 9 | — | — | — |
Total Debt
|
|||
| (132) | (127) | (88) | 35 | 159 | 131 | (41) | (4) | (5) | (7) |
Net Debt
|
|||
| 127 | 130 | 98 | 9 | (124) | (94) | 35 | 29 | 27 | 27 |
Sh' Equity
|
|||
| (83.14%) | (53.85%) | (74.67%) | (73.71%) | (82.00%) | (98.22%) | 86.17% | (15.37%) | (5.31%) | (1.49%) |
ROA
|
|||
| 0.00% | (1,749.59%) | (875.89%) | (212.33%) | (274.11%) | (131.56%) | 0.00% | (21.34%) | (17.12%) | (14.15%) |
ROIC
|
|||
| (94.33%) | (59.77%) | (116.62%) | (330.09%) | 319.73% | 158.45% | (383.04%) | (31.90%) | (7.70%) | (2.10%) |
ROE
|
|||
TherapeuticsMD, Inc. peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AYTU Aytu BioPharma, Inc. | $25.1M | 0.0× | Compare |
| UPC Universe Pharmaceuticals INC | $23.5M | 0.0× | Compare |
| CPHI China Pharma Holdings, Inc. | $31.8M | 0.0× | Compare |
| BFRI Biofrontera Inc. | $17.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| RMTI Rockwell Medical, Inc. | $34.5M | 0.0× | Compare |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $15.6M | 34.7× | Compare |
| ZYBT Zhengye Biotechnology Holding Limited | $40.1M | — | Compare |
| IXHL Incannex Healthcare Inc. | $40.7M | 0.0× | Compare |
TherapeuticsMD, Inc. (TXMD) key facts
- TherapeuticsMD, Inc. (TXMD) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- TherapeuticsMD, Inc. reported a net loss of $569,000.00, or a loss of $0.05 per share, for fiscal 2025.
- As of September 25, 2026, TXMD traded at $2.05, a market capitalization of $24.7 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 7.3× sales.
- Return on equity was −2.10% and debt-to-equity 0.00.
TherapeuticsMD, Inc. (TXMD) Latest News
11 Aug
TherapeuticsMD, Inc. (TXMD) announced its financial results for the second quarter of 2026. Quarterly earnings releases can shift near-term stock valuation and sentiment without altering long-term strategy.
12 May
TherapeuticsMD, Inc. (TXMD) announced First Quarter 2026 financial results. Quarterly financial results disclosure influences TXMD's reported performance, investor sentiment, and short-term market valuation.
30 Mar
TherapeuticsMD, Inc. (TXMD) announced full-year 2025 financial results. Full-year financial results announcement represents a major disclosure influencing stock price, investor sentiment, and future performance trajectory.
12 Nov
TherapeuticsMD, Inc. reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its women's health products, with ongoing efforts to enhance market presence and drive sales. Despite challenges in the market, TherapeuticsMD remains committed to its strategic initiatives aimed at improving performance and shareholder value. The earnings report indicates moderate financial performance and operational focus that may influence investor sentiment and market positioning.
TherapeuticsMD, Inc. (TXMD) reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue, net income, and operational developments. The company continues to focus on its product pipeline and strategic initiatives aimed at enhancing market presence and shareholder value. Management provided insights into future expectations and ongoing projects, indicating a commitment to growth and innovation in women's health. The financial results and strategic initiatives may moderately influence the company's performance and market sentiment.
TherapeuticsMD announces third quarter 2024 financial results. The financial results may affect the company's financial performance and competitive positioning.
12 Aug
TherapeuticsMD, Inc. reported its Q2 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its product pipeline and market strategies, aiming to enhance its position in the women's health sector. Despite challenges, management expressed optimism about future growth and ongoing initiatives. The earnings report indicates moderate financial performance and operational updates that may influence investor sentiment and market positioning.
TherapeuticsMD, Inc. (TXMD) reported its financial results for the second quarter of 2025, highlighting key metrics such as revenue, expenses, and net income. The company continues to focus on its product pipeline and strategic initiatives aimed at enhancing market presence and operational efficiency. Management provided insights into future expectations and ongoing projects, indicating a commitment to growth and innovation in women's health therapeutics. The financial results and strategic initiatives may moderately influence the company's performance and market positioning.
TherapeuticsMD reported a net loss in the second quarter of 2024, with a decrease in license revenue and operating expenses. The company is exploring strategic alternatives. The financial results and exploration of strategic alternatives may moderately influence TherapeuticsMD's future performance.
13 May
TherapeuticsMD, Inc. reported a net loss of $636 thousand for Q1 2025, an improvement from a loss of $809 thousand in Q1 2024. License revenues increased by 25.8% to $393 thousand, driven by changes in sales of licensed products. Total operating expenses decreased by 13.1% to $1,264 thousand due to increased efficiencies. The company is exploring strategic alternatives, including potential acquisitions or mergers, but has not set a timetable for completion. As of March 31, 2025, cash and cash equivalents totaled $5.7 million. The company's exploration of strategic alternatives and improved financial metrics may moderately influence its future performance.
29 Mar
TherapeuticsMD (NASDAQ:TXMD) reported a net loss of US$2.31 million for the full year 2024, a 70% improvement from FY 2023, with a loss per share of US$0.20 compared to US$0.74 in the previous year. Shares have increased by 10% over the past week. However, there are three warning signs identified for the company, one of which raises concern. The significant narrowing of losses indicates potential for improved financial performance, but risks remain that could limit overall impact.
TherapeuticsMD announces full year 2023 financial results. The financial results may moderately influence the company's performance and competitive positioning.
27 Mar
TherapeuticsMD, Inc. reported a net loss of $2.3 million for the year ended December 31, 2024, a significant improvement from a $7.7 million loss in 2023. License revenue increased by 35.3% to $1.8 million, driven by changes in sales of licensed products. Total operating expenses decreased by 33.6% to $6.5 million due to cost optimization as the company transitions to a royalty-based business model. The company is exploring strategic alternatives, including potential acquisitions or mergers, but has not set a timetable for this process. As of December 31, 2024, cash and cash equivalents totaled $5.1 million. The company's transition to a royalty-based model and exploration of strategic alternatives may moderately influence its financial performance and market positioning.
3 Jan
TherapeuticsMD, Inc. (TXMD) is one of the three US penny stocks with over $9M market cap. The news of TherapeuticsMD, Inc. being highlighted as a promising penny stock with a significant market cap is likely to have a significant impact on its future performance and investor sentiment.
10 May
TherapeuticsMD reported financial results for Q1 2024, with net loss from continuing operations, license revenues, and total operating expenses disclosed. The financial results and strategic evaluation mentioned in the article could moderately influence the company's future performance.
14 Nov
TherapeuticsMD reports third quarter 2023 financial results, focusing on cost control and evaluating strategic alternatives. The evaluation of strategic alternatives and transition to a royalty-based business could significantly impact the company's future trajectory and market performance.
14 Aug
TherapeuticsMD reported Q2 2023 financial results, transitioning to a royalty-based business. Transition to royalty-based business may moderately influence financial performance and competitive positioning.
15 May
TherapeuticsMD reported financial results for Q1 2023, showing a decrease in net loss and operating expenses. Transition to a royalty-based business model may moderately influence financial performance and competitive positioning.